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Endometrial cancer (EC) is the leading malignant tumor occurring in the female genital tract and some subtypes
are highly invasive and metastatic. miRNAs are small non-coding RNAs that have a broad impact on cancer
progression. In particular, miR-194 regulates epithelial to mesenchymal transition (EMT) by suppressing the
expression of BMI-1 in EC. In this retrospective study, the clinical significance of miR-194 was investigated in archival
EC specimens. We extracted total RNA from thirty-two EC samples and quantified the expression level of miR-194.
We discovered that the expression level of miR-194 was significantly (P = 0.03) lower in type I EC patients with
more advanced stage. In addition, patients with higher miR-194 levels have better prognosis than those with lower
miR-194 levels (P = 0.0067; Cut-off value of miR-194 = 0.3). These results indicate that miR-194 has potential to
serve as prognostic biomarker for EC patients.
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Endometrial cancer (EC) is the most frequent malignant
tumor occurring in the female genital tract in the United
States [1]. Generally EC cases can be classified into two
broad categories based on their clinical and pathological
features. Around 80% of all the EC cases are Type I EC,
endometrioid EC (EEC), which are estrogen-dependent.
Most of EEC cases are low stage and low grade, and
have a better prognosis [2]. In contrast, Type II EC cases
are not dependent on estrogen and have more cases in
advanced stages, especially serous carcinomas (ESC) or
clear-cell carcinomas (CCC), which constitute approxi-
mately 10% of all the EC cases. These types of EC are
shown to be more aggressive, and have a poor prognosis
[2]. Although overall 5-year survival rate of EC patients
is relatively higher than those of other gynecologic
cancers, around 80% among all stages, certain histo-
logical types of endometrial cancer are highly invasive
and easily metastatic with low survival rate [3]. Thus
there is an emerging need for highly sensitive and spe-
cific molecular prognostic biomarkers besides the* Correspondence: jingfang.ju@stonybrookmedicine.edu
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reproduction in any medium, provided the orpathological diagnosis based on the morphological
alterations, to better predict the outcome of EC.
In the past 10 years, small regulatory RNAs have gained
enormous interests in cancer research. microRNAs
(miRNAs) are a class of non-coding RNA molecules, 18–25
nucleotides in length, that regulate the expression of their
target genes by translational arrest or mRNA cleavage
mostly via direct interaction with the 30-UTRs of the target
mRNAs [4,5]. Base pairing between at least six consecutive
nucleotides within the 50-seed of the miRNA with the tar-
get site on the mRNA is reported to be a minimum re-
quirement for the miRNA-mRNA interaction [6]. miRNAs
have been found to regulate many cellular processes includ-
ing apoptosis [7-10], differentiation [5,11,12] and cell
proliferation [7,12-14]. Several reports indicate that
aberrant expression levels of certain miRNAs in both
plasma and cancer tissue correlates with the EC
patients’ survival rate, which can be used as predictive
biomarkers [15-17].
Recently the expression pattern and function of miR-
194 has been widely studied in various cancers but
remains controversial. miR-194 was found to be up-
regulated in cancerous tissue when compared to adjacent
normal tissue in the esophagus, and its expression level is
higher in adenocarcinoma tissue than in squamous cell
carcinoma [18]. In addition, the overexpression of miR-. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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adenocarcinoma (PDAC) cell lines [19]. However, other
reports discovered that miR-194 level was down-regulated
in colon cancer, colorectal liver metastases, liver cancer
and nephroblastomas [20-23], indicating the function of
miR-194 is dependent on its cellular context. Ectopic
overexpression of miR-194 has been shown to enhance
the colon cancer angiogenesis in vivo through inhibition
of its target – thrombospondin-1 [24]. In breast cancer
cells, the inhibition of HER2 by monoclonal antibody led
to upregulation of miR-194. Overexpression of miR-194
induced the inhibition of its target, talin 2, and in turn
reduced cell migration and invasion [25]. Similarly, studies
from our group have demonstrated the functional signifi-
cance of miR-194 in endometrial cancer by suppressing
BMI-1 expression to regulate epithelial to mesenchymal
transition [26]. Our results show that ectopic expression
of miR-194 in EC cells inhibited its target, BMI-1, to
prevent EMT and inhibit tumor invasion. Additional
miR-194 targets involved in EMT or metastasis were
reported in liver cancer, including N-cadherin, RAC1,
heparin-binding epidermal growth factor-like growth
factor (HBEGF), type 1 insulin-like growth factor re-
ceptor (IGF1R) [20].
In this study, we investigated the clinical significance
of miR-194 in EC. We quantified the expression level of
miR-194 in archival formalin fixed paraffin embedded
(FFPE) EC clinical specimens. The expression levels of
miR-194 were then correlated with clinical parameters
such as disease stage, disease type, and patient survival.
Our results show that miR-194 is significantly associated
with histology Type I EC. Kaplan-Meier survival analysis
revealed that high levels of miR-194 are associated
with a longer survival. As a result, miR-194 may have
a potential as a novel prognostic biomarker for EC
patients.Figure 1 miR-194 expression level decreased in type I EC samples of
categorized based on pathology stage. There is no significant difference betw
(A, P = 0.2295) or type II EC (C, P = 0.7956). However miR-194 expression leveResults and discussion
Expression level of miR-194 is inversely correlated with
cancer stage in type I EC
In this study, we needle dissected EC tissues from thirty-
two FFPE EC specimens and extracted RNAs to quantify
the relative expression level of miR-194. We then
seperated the patients into two clinical groups based on
their pathology reports, early stage (stage I and II) and late
stage (stage III and IV). Our analysis results show a trend
that the miR-194 level was lower in late stage EC samples
(Figure 1A) but not statistically significant (P = 0.2295).
To determine whether this expression pattern was
associated with histology type, we further seperated the
patients based on their histology type (type I and II EC)
and clinical stage. We found that miR-194 expression level
was significantly downregulated in late stage type I EC
samples (Figure 1B, P = 0.0323), however no significant
correlation was found in type II EC samples (Figure 1C).
It has been reported that miR-194 regulates cell migra-
tion and invasion in various cancer types, including EC,
breast cancer and liver cancer [20,25,26]. Especially in
EC, the target of miR-194 was found to be BMI-1 [26],
an important oncogene regulating EMT [27]. We have
further demonstrated in our previous studies the func-
tional significance of miR-194 in regulating EMT transi-
tion in endometrial cancer by regulating the expression
of E-cadherin and vimentin [26]. Overexpression of
BMI-1 has been found in many human cancers, includ-
ing lung cancer, prostate cancer, breast cancer, ovarian
cancer and EC [28-32]. The Knockdown of BMI-1 in EC
cell lines showed similar phenotypes as ectopic ex-
pression of miR-194, which led to upregulation of
E-cadherin, downregulation of Vimentin and impair-
ment in cell invasion [26]. Consistent with these results,
our data showed lower expression of miR-194 in stage
III and IV type I EC samples when compared to stage Ihigher stage. The miR-194 expression level in EC samples was
een early stage (I, II) and late stage (III, IV) in overall EC samples
l was lower in late stage than early stage in type I EC (B, P = 0.0323).
Figure 2 miR-194 expression level can be used as a prognostic biomarker for EC patients. Kaplan-Meier survival analysis of EC patients
based on miR-194 expression level. The cut-off expression value of miR-194 = 0.3 (P = 0.0067).
Table 1 Clinical features of the 32 endometrial cancer
patients
Characteristics Frequency Percentage (%)





Type II EC 17 53.1
Serous carcinoma 8 25
Clear cell carcinoma 5 15.6
Malignant mixed mullerian tumor 3 9.4

















Zhai et al. Biomarker Research 2013, 1:12 Page 3 of 5
http://www.biomarkerres.org/content/1/1/12and II samples, indicating miR-194 was inversely cor-
related to the cancer aggresiveness. However we did not
find any difference in miR-194 expression level in type II
EC samples or overall EC samples. One possible reason is
that our clinical samples consisted of both type I and II
EC samples, which have distinct clinical features. And the
seventeen type II EC samples consisted of four different
histology subtypes, which contributed to the sample com-
plexation. Larger EC patient cohorts are clearly needed in
future studies to fully validate our findings. In addition,
due to the limitation of FFPE tissue, we were not able to
quantify the protein expression levels of key known miR-
194 targets such as BMI-1 and TMP1.
Expression level of miR-194 correlated with EC patients’
suvival time
Since we show that miR-194 is inversely correlated with
EC aggressiveness, we reason that miR-194 expression
level may affect EC patients’ survival. EC patient survival
was analyzed by Kaplan-Mirer survival analyses with
miR-194 expression cut-off values as 0.3 (Figure 2). We
found that the median survival time of EC patients with
low miR-194 levels (less than 0.3) was 14 months, which
was significantly shorter than those with higher miR-194
levels (greater than 0.3), 85 months. The overall survival
rates of these two groups were significantly different
(P = 0.0067), which was independent of the histological
type. This is highly consistent with the previous reports
that elevated miR-194 target BMI-1 expression is as-
sociated with increased tumor invasion and metastasis
in endometrial cancer [26].
As previous reported, aberrant expression of miRNAs
was observed in most tumor types, and multiple clinical
screenings showed that miRNAs have a potential to serve
as prognostic biomarkers in cancers [33-35]. Moreover,
the superior stability of miRNAs in FFPE tissues andvarious body fluids (plasma, serum, etc.) further facilitates
the clinical utility of miRNAs [36,37]. Our previous stu-
dies found that miR-205 was overexpressed in EC tissue
compared to adjacent normal tissues, and expression le-
vels of miR-205 were significantly inversely correlated with
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a critical regulator of EMT transition by suppression of
BMI-1, was inversely correlated with patient survival rate,
implicating miR-194 as a new candidate prognostic bio-
marker in EC patients.
Conclusion
Since miRNAs can regulate the expression of multiple
targets, they have a broader impact on cancer progres-
sion. Due to their superior stability in FFPE tissue, they
can be used as diagnostic and prognositic biomarkers for
cancer patients. In this study we discovered that the
miR-194 expression level was down-regulated in late
stage, type I EC patients. The inverse correlation between
miR-194 expression level and EC patients’ survival time
was independent of histological subtype. These results
suggested that miR-194 has potential to serve as a prog-
nostic biomarker for EC patients. Future studies with large
multi-center patient cohorts are needed to fully validate
the potential of miR-194 as a prognostic biomarker in EC.
Methods
Patients and Samples
Thirty-two endometrial cancer patients, who underwent
hysterectomy at Stony Brook University Medical Center,
Stony Brook, NY, USA, were selected from 1995 to
2010. Patient consent forms were obtained from each
patient according to the policies of Institution Review
Board. Patient clinical information was provided by the
Cancer Registry of Stony Brook University Medical Cen-
ter, which reported data about patient age, sex, treat-
ment, tumor recurrence and survival for up to 15 years.
The characteristics of these patients are shown in
Table 1. Representative tissue blocks from each case
were assembled from the archival collections of the De-
partment of Pathology, and used for subsequent analysis.
RNA Isolation
From the archival FFPE tissues, areas of endometrial
cancer were identified using the corresponding
hematoxylin and eosin (H&E) stained sections and cores
measuring 1.5 mm in diameter and 2 mm in length (ap-
proximately 0.005 g) were extracted. Then the samples
were deparaffinized with xylenes, hydrated by using de-
creasing concentrations of ethanol, and digested with
proteinase K. Total RNA was isolated with Trizol re-
agent according to the manufacture’s protocol (Life
Technologies, CA, USA).
Real time qRT-PCR analysis of miRNA expression
All reagents for real-time qRT-PCR were ordered from
Life technologies. For quantification of miR-194, 10 ng
of RNA was used as a template and cDNA was
synthesized with high capacity cDNA synthesis kit andmiRNA-specific primers (miR-194 and internal control
RNU44). Then the cDNA templates were mixed with
gene-specific primers for miR-194 and RNU44, and
Taqman 2x universal PCR master mix. Applied
Biosystems 7500 Real-Time PCR machine was used for
qRT-PCR and programmed as: 95°C, 10 minutes; 95°C,
15 seconds; 60°C, 1 minute, which were repeated for 40
cycles. Fluorescent signals from each sample were
collected at the endpoint of every cycle, and the expres-
sion level of genes and miR-194 was calculated by ΔCT
values based on the internal control, normalized to one
control sample from normal endometrium and plotted
as relative value (RQ).
Statistical Analysis
All statistical analyses were performed using GraphPad
Prism software 5.0. Kaplan-Meier survival curves were
generated to examine the relationship between the ex-
pression levels of miR-194 and patients’ survival rate.
The statistical significance between two groups was
determined using unpaired Student’s t-test with Welch’s
correction. Data were expressed as mean ± standard
error of the mean (SEM). The statistical significance is
described in figure legends.
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